NEW YORK (GenomeWeb) – Myriad Genetics and other patent owners have settled their BRCA testing patent lawsuit with Pathway Genomics and Invitae.

Myriad sued Pathway on June 13, 2014, for infringement of its patent claims underlying BRCA1 and BRCA2 genetic testing. The legal tussle began soon after Pathway launched a next-generation sequencing test for gauging alterations in BRCA1 and BRCA2 genes, called BRCATrue.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.